Kardigan was able to upsize its IPO, raising more cash for three drug candidates in mid-stage clinical development for cardiovascular conditions with no available therapies. All three programs are expected to report key data in 2027 that could pave the way for Phase 3 testing.
The post Kardigan’s IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases appeared first on MedCity News.
